Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Rasmussen

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Current Opinion in Virology|May 4, 2019
Between a shock and a hard place: challenges and developments in HIV latency reversalJennifer M Zerbato, Harrison V Purves, Sharon R Lewin, et al.
STAR Protocols|August 8, 2024
Protocol for measuring killing capacity and intracellular cytokine production of human HIV antigen-specific CD8 T cells using flow cytometryCéline Gubser, Rachel D Pascoe, Lydie Trautmann, et al.
Journal of Virology|February 17, 2017
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing AgentsJanka Petravic, Thomas A Rasmussen, Sharon R Lewin, et al.
Journal of Virology|October 13, 2017
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Deborah Cromer, Mykola Pinkevych, Thomas A Rasmussen, et al.
Journal of Virology|February 19, 2016
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T CellsRasmus Offersen, Sara Konstantin Nissen, Thomas A Rasmussen, et al.
Journal of Virus Eradication|February 15, 2021
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settingsJillian Sy Lau, Thomas A Rasmussen, Sharon R Lewin, et al.
AIDS (London, England)|September 5, 2021
Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral reboundMichael J Corley, Alina P S Pang, Thomas A Rasmussen, et al.
BMJ (Clinical Research Ed.)|September 19, 2012
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort studyThomas A Rasmussen, Martin R S Jørgensen, Stephanie Bjerrum, et al.
AIDS (London, England)|June 19, 2010
Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapyOle S Søgaard, Henrik C Schønheyder, Anne R Bukh, et al.
Iscience|November 29, 2023
GITR activation <i>ex vivo</i> impairs CD8 T cell function in people with HIV on antiretroviral therapyCéline Gubser, Rachel D Pascoe, Judy Chang, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Current Opinion in Virology|May 4, 2019
Between a shock and a hard place: challenges and developments in HIV latency reversalJennifer M Zerbato, Harrison V Purves, Sharon R Lewin, et al.
STAR Protocols|August 8, 2024
Protocol for measuring killing capacity and intracellular cytokine production of human HIV antigen-specific CD8 T cells using flow cytometryCéline Gubser, Rachel D Pascoe, Lydie Trautmann, et al.
Journal of Virology|February 17, 2017
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing AgentsJanka Petravic, Thomas A Rasmussen, Sharon R Lewin, et al.
Journal of Virology|October 13, 2017
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Deborah Cromer, Mykola Pinkevych, Thomas A Rasmussen, et al.
Journal of Virology|February 19, 2016
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T CellsRasmus Offersen, Sara Konstantin Nissen, Thomas A Rasmussen, et al.
Journal of Virus Eradication|February 15, 2021
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settingsJillian Sy Lau, Thomas A Rasmussen, Sharon R Lewin, et al.
AIDS (London, England)|September 5, 2021
Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral reboundMichael J Corley, Alina P S Pang, Thomas A Rasmussen, et al.
BMJ (Clinical Research Ed.)|September 19, 2012
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort studyThomas A Rasmussen, Martin R S Jørgensen, Stephanie Bjerrum, et al.
AIDS (London, England)|June 19, 2010
Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapyOle S Søgaard, Henrik C Schønheyder, Anne R Bukh, et al.
Iscience|November 29, 2023
GITR activation <i>ex vivo</i> impairs CD8 T cell function in people with HIV on antiretroviral therapyCéline Gubser, Rachel D Pascoe, Judy Chang, et al.
Pageof 7